Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V937 + Pembrolizumab in Advanced/Metastatic Melanoma
NCT04152863Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2020
- Primary completion
- Jul 2023
- Modality
- Oncolytic Viruses, Microbiome Therapeutics
- Countries
- 11
01
Overview
A Phase 2 trial of gebasaxturev in melanoma, sponsored by Merck & Co.. Started Jun 2020; status: terminated.
02
Drugs
gebasaxturev
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04152863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04152863.